Interim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual Meeting
SAN DIEGO, April 07, 2024 -- Replimune Group, Inc. , a clinical stage biotechnology company pioneering the development of a novel portfolio of oncolytic immunotherapies, today announced the...
Source: marketscreener.com